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Abstract
Fine mapping of human cytotoxic T lymphocyte (CTL) responses against hepatitis C virus (HCV) is based on external loading
of target cells with synthetic peptides which are either derived from prediction algorithms or from overlapping peptide
libraries. These strategies do not address putative host and viral mechanisms which may alter processing as well as
presentation of CTL epitopes. Therefore, the aim of this proof-of-concept study was to identify naturally processed HCV-
derived major histocompatibility complex (MHC) class I ligands. To this end, continuous human cell lines were engineered
to inducibly express HCV proteins and to constitutively express high levels of functional HLA-A2. These cell lines were
recognized in an HLA-A2-restricted manner by HCV-specific CTLs. Ligands eluted from HLA-A2 molecules isolated from
large-scale cultures of these cell lines were separated by high performance liquid chromatography and further analyzed by
electrospray ionization quadrupole time of flight mass spectrometry (MS)/tandem MS. These analyses allowed the
identification of two HLA-A2-restricted epitopes derived from HCV nonstructural proteins (NS) 3 and 5B (NS31406–1415 and
NS5B2594–2602). In conclusion, we describe a general strategy that may be useful to investigate HCV pathogenesis and may
contribute to the development of preventive and therapeutic vaccines in the future.
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Introduction
With an estimated 120–180 million chronically infected individ-
uals, HCV is a leading cause of chronic hepatitis, liver cirrhosis and
hepatocellular carcinoma worldwide [1]. Antiviral therapy has
improved considerably with the introduction of pegylated interfer-
on-a and ribavirin as well as, more recently, the first generation of
directly acting antivirals. However, many patients still do not
respond to or cannot tolerate antiviral therapy. In addition, HCV
continues to be transmitted in certain areas of the world [2].
Therefore, the development of preventive and therapeutic vaccines
against hepatitis C is of major public health importance [3].
Innate and adaptive immune responses to HCV have been
studied in great detail [4]. Resolution of acute hepatitis C correlates
with the induction of strong and broad CD4+ and CD8+ T cell
responses [5]. However, the majority of patients fail to eliminate
HCV and develop chronic infection (reviewed in [5,6]). The high
genetic variability of HCV significantly contributes to the escape
from the immune system and complicates the development of an
efficient vaccine [7]. Nevertheless, more recent data indicate that
there is protective immunity against HCV [4].
A critical step for the understanding of the immunopathogenesis
of HCV infection and HCV clearance is the presentation of viral
epitopes on MHC class I molecules from infected cells. Most of the
currently available experimental systems are limited, since an a
priori defined set of synthetic peptides is used to either externally
load target cells or to expand epitope-specific CD8+ T cells which
are then used in downstream readout applications.
Therefore, the aim of this study was to identify specific MHC
class I ligands which are naturally processed and presented by cells
expressing HCV proteins. To this end, we engineered continuous
human cell lines to inducibly express HCV proteins and to
constitutively express high levels of functional HLA-A2. MHC
class I molecules were isolated from large-scale cultures of these
cell lines, followed by elution and identification of naturally
processed CTL epitopes. This proof-of-concept study allowed the
identification of two naturally processed HCV-derived MHC class
I ligands. Although both epitopes have been described previously
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29286
by conventional T-cell dependent methods, this novel approach
has the potential to identify novel and unconventional epitopes.
Results
Generation of stable cell lines inducibly expressing HCV
proteins and constitutively expressing functional HLA-A2
To identify naturally processed HCV MHC class I ligands by
mass spectrometry (MS), as described in this manuscript, U-2 OS
human osteosarcoma-derived cell lines UNS3-4A-24 and UHCV-
con-57.3 [8,9] were used. These cells allow for tight, tetracycline-
regulated expression of the HCV nonstructural protein 3-4A
(NS3-4A) complex or of the entire viral polyprotein, respectively.
However, U-2 OS cells express low levels of endogenous HLA-A2
[10]. To enhance MHC class I presentation of HCV antigens,
UNS3-4A-24 and UHCVcon-57.3 cells were engineered to
overexpress HLA-A2. Clones UNS3-4A/A2-27.35 and UHCV/
A2-27 were used in this study. As shown in Figure 1 (panels A and
B), these cells allow for tightly regulated expression of HCV
proteins, as documented by immunoblot and indirect immuno-
fluorescence microscopy. NS3 was identified in both cell lines at
the expected molecular mass of 70 kDa. Detection of NS5A at the
expected molecular mass of 56 kDa demonstrates correct viral
polyprotein processing in UHCV/A2-27 cells. Furthermore, cells
were analyzed for HLA-A2 surface expression by flow cytometry
(Fig. 1C). Compared to the founder cells, both cell lines showed an
enhanced level of HLA-A2 surface expression. Furthermore,
strong HLA-A2 expression could also be detected after withdrawal
of tetracycline from the culture medium and induction of HCV
protein expression (data not shown). This is a prerequisite for the
elution of HCV proteins from MHC class I molecules isolated
from these cells and demonstrates that HCV protein expression
does not interfere with HLA-A2 surface expression.
Targeting of UNS3-4A/A2-27.35 and UHCV/A2-27 cells by
HCV-specific CD8+ CTL
To explore whether UNS3-4A/A2-27.35 and UHCV/A2-27
cells can serve as targets for HCV-specific CTL, cell lines were
cocultured with CD8+ T cell lines that have been raised to
recognize epitopes localized in NS3 (B7, CINGVCWTV) or NS5B
(B22, ALYDVVTKL), respectively. T cell activation was assessed
by intracellular IFN-c staining and flow cytometry. As shown in
Figure 2A, CTL lines were activated specifically after external
loading with the corresponding synthetic peptide. More important,
coculture of UNS3-4A/A2-27.35 and UHCV/A2-27 cells with
CD8+ T cell lines demonstrated their potential to endogenously
express and functionally present HCV epitopes (Fig. 2B). Cocul-
ture of UNS3-4A/A2-27.35 and UHCV/A2-27 cells leads to
efficient activation of the CD8+ T cell line which recognizes the
B7 epitope located in NS3. By contrast, and as expected, the
Figure 1. Cell lines UNS3-4A/A2-27.35 and UHCV/A2-27. (A)
Indirect immunofluorescence microscopy of UNS3-4A/A2-27.35 and
UHCV/A2-27 cells cultured for 48 h in the presence (+ tet) or absence
(2 tet) of tetracycline. Monoclonal antibody 1B6 against HCV NS3 was
used as primary antibody. (B) Immunoblot analysis of UNS3-4A/A2-
27.35 and UHCV/A2-27 cells were cultured for 48 h in the presence
(+ tet) or absence (2 tet) of tetracycline. Monoclonal antibodies 1B6
against HCV NS3 or 11H against NS5A were used as primary antibodies.
(C) Left panel: HLA-A2 surface expression of UNS3-4A/A2-27.35 (blue
histogram) compared to the founder cell line UNS3-4A-24 (red
histogram). Right panel: HLA-A2 surface expression of UHCV/A2-27
(blue histogram) compared to the founder cell line UHCVcon-57.3 (red
histogram).
doi:10.1371/journal.pone.0029286.g001
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CD8+ T cell line specific for the B22 epitope in NS5B recognizes
only UHCV/A2-27 cells. No CTL reactivity was observed when
target cells were cultured in the presence of tetracycline, i.e. when
they did not express HCV proteins. These results validate both cell
lines as functional targets for HCV-specific CD8+ T cells and
demonstrate that naturally processed HCV epitopes are efficiently
presented on HLA-A2 molecules in this model system.
Large-scale expansion of UNS3-4A/A2-27.35 and UHCV/
A2-27 cells, isolation of MHC class I molecules and
peptide elution
To obtain the required amounts of HLA-A2 with naturally
processed ligands, UNS3-4A/A2-27.35 and UHCV/A2-27 cells
were expanded to large scale, yielding cell pellets of 60 ml each.
From these, 1.5 and 7.0 nmol MHC class I molecules were
isolated, respectively. The yield of HLA molecules (as determined
by Edman degradation) corresponds to 25 and 117 pmol per gram
of cells, respectively. According to our experience, such values are
typical for tumor cells that do not have abundant HLA expression
[11]. The higher yield from UHCV/A2-27 cells presumably
correlates with higher HLA-A2 expression. Subsequently, ligands
were eluted from MHC class I molecules, as described in the
Materials and Methods section and as illustrated schematically in
Figure 3.
Detection of HCV-derived peptides in MHC class I ligands
isolated from UNS3-4A/A2-27.35 and UHCV/A2-27 cells
Naturally processed MHC class I ligands of UNS3-4A/A2-
27.35 and UHCV/A2-27 cells were separated by high perfor-
mance liquid chromatography (HPLC) and analyzed by electro-
Figure 2. Targeting of UNS3-4A/A2-27.35 and UHCV/A2-27 cells by HCV-specific CD8+ CTL. CD8+ T cell lines B7 and B22, targeting
epitopes CINGVCWTV derived from NS3 and ALYDVVTKL localized in NS5B, respectively, were used for coculture experiments. (A) Stimulation of T cell
lines with the corresponding synthetic peptide leads to their activation, as indicated by the expression of IFN-c. For all dot blots in this figure, CD8 is
displayed on the abscissa and IFN-c expression on the ordinate. (B) UNS3-4A/A2-27.35 and UHCV/A2-27 cells cultured for 48 h in the presence (+ tet)
or absence (2 tet) of tetracycline were cocultured with CD8+ T cell lines. In the presence of tetracycline, no substantial activation of the T cell lines
could be observed. However, strong activation was observed after loading of UNS3-4A/A2-27.35 and UHCV/A2-27 cells with the corresponding
synthetic peptide. By contrast, the NS3-specific B7 cell line was activated efficiently by UNS3-4A/A2-27.35 and UHCV/A2-27 cells cultured in the
absence of tetracycline while the NS5B-specific B22 cell line could be stimulated only by UHCV/A2-27 cells, which upon tetracycline withdrawal
express the entire HCV polyprotein. When target cells were cultured in the absence of tetracycline, T cell activation was enhanced only slightly by
external peptide loading.
doi:10.1371/journal.pone.0029286.g002
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spray ionization (ESI) quadrupole time of flight (Q-TOF) mass
spectrometry (MS)/tandem MS, as described in the Materials and
Methods section. HPLC and MS of predicted synthetic peptides
allowed to screen for epitopes of interest in ligand preparations
and subsequent sequence verification by online liquid chromatog-
raphy (LC) MS analysis. With this approach, two naturally
processed MHC class I ligands could be identified. The peptide
isolated from UNS3-4A/A2-27.35 cells is derived from NS3 (HCV
polyprotein position 1406–1415; NS3-4A1406–1415) with the amino
acid sequence KLVALGINAV (Fig. 4). The epitope isolated from
UHCV/A2-27 cells is derived from NS5B (HCV polyprotein
position 2594–2602; NS5B2594–2602) with the amino acid sequence
ALYDVVSKL (Figures S1 and S2) that is cross-recognized by
epitope ALYDVVTKL-specific T cells (Fig. 2) in spite of the
threonine instead of serine in position 2600.
Discussion
In this proof-of-concept study, we identified two naturally
processed HCV-derived MHC class I ligands. These were isolated
from cell lines UNS3-4A/A2-27.35 and UHCV/A2-27, allowing
the tightly regulated expression of HCV NS3-4A and of the entire
viral polyprotein, respectively, as well as the constitutive expression
of functional HLA-A2. These cell lines were specifically recognized
by HCV-specific CTL, indicating efficient presentation of
naturally processed MHC class I ligands. MHC class I molecules
were purified by immunoprecipitation. Ligands were eluted,
separated by HPLC and sequenced by ESI Q-TOF-MS/MS.
Among other MHC class I ligands, two naturally processed HCV
epitopes, NS31406–1415 and NS5B2594–2602 were identified. Inter-
estingly, both had been described previously, based on prediction
algorithms [12,13].
HCV replication occurs within the cytoplasm of infected cells.
Translation and processing of the viral polyprotein take place in
close association with membranes of the endoplasmic reticulum.
HCV proteins are then subjected to cellular antigen-processing
pathways, resulting in the presentation of HCV epitopes on the
cell surface. It has been estimated that approx. 2,000–10,000
molecules of a protein are required to allow the presentation of
one antigen [14]. In fact, antigen processing involves a highly
complex interplay of multiple steps and factors. Degradation by
the proteasome, interaction with chaperones such as calnexin,
incorporation into the peptide loading complex, involving other
chaperones such as tapasin, peptide trimming by aminopeptidases,
loading onto empty MHC I molecules, and, finally, transport
across the secretory pathway to the cell surface are pivotal steps
that are tightly coordinated during this process. Several approach-
es typically used to identify MHC I epitopes bypass this complex
process, which could be one reason why they eventually fail to
identify relevant epitopes. These approaches include (i) the
induction and identification of T cells through the stimulation
with defined synthetic peptides and (ii) the generation of epitope-
specific T cell lines which are subsequently tested for their
reactivity with cells expressing a given antigen. There are several
potential limitations of these systems as they are restricted by the
use of synthetic peptides or depend on the presence of functional
HCV-specific T cells.
Against this background, a direct T cell-independent identifi-
cation of naturally processed MHC class I epitopes would be
desirable. In this context, we have demonstrated that peptide
elution from HCV protein-expressing cell lines and subsequent
direct sequencing by ESI Q-TOF MS/MS is a feasible and
powerful approach. Using this experimental setting, UNS3-4A/
A2-27.35 and UHCV/A2-27 cells turned out to be valuable tools
which could be further employed to study HCV antigen
processing and presentation in the future. The identification of
two known HCV HLA-A2 ligands that are localized in NS3 and
NS5B demonstrates their authentic processing and presentation in
vivo. Furthermore, a more elaborate approach, using tracer
substances such as isotope-labeled peptides, might hold promise
for the quantification of an epitope relative to the complete
repertoire of presented ligands. Few reports on Epstein-Barr virus-
encoded proteins investigated how the amount of presented MHC
I antigen complex could influence the efficiency of recognition by
CD8+ T cells [15,16]. Therefore, in addition to the proof-of-
principle of this particular experimental setting, the identification
of the two epitopes by this novel approach underlines their
importance as natural targets for HCV-specific T cells. CTL
responses against these epitopes could be of particular importance
to control viral infection and may be included as targets in future
vaccination strategies.
In principle, the direct sequencing of MHC I ligands should
allow to identify epitopes after posttranslational protein modifica-
tions such as glycosylation, phosphorylation and proteolytic
processing as well as unconventional epitopes derived from
alternative reading frames or RNA splicing that are not detected
by the current conventional methods. Future studies aimed at
identifying naturally processed HCV-derived MHC class I ligands
may provide novel insights into epitope processing and presenta-
Figure 3. Identification of naturally processed HLA-A2 ligands.
Following large-scale expansion, cell pellets were lysed and MHC class I
molecules with bound ligands were purified by immunoprecipitation.
Subsequently, ligands were eluted and separated by high performance
liquid chromatography (HPLC). Fractions of interest were sequenced by
mass spectrometry.
doi:10.1371/journal.pone.0029286.g003
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Figure 4. Detection and characterization of peptide NS31406–1415 in MHC class I ligands isolated from UNS3-4A/A2-27.35 cells.
Naturally processed MHC class I ligands of UNS3-4A/A2-27.35 cells were separated by high performance liquid chromatography (HPLC) and analyzed
by mass spectrometry. (A) A chromatogram of the total ion current (TIC) is shown. (B) The mass chromatogram of ionized peptides with m/z = 499.3
reveals a peak at retention time t = 49.5 min that correlates with (C) a signal of the synthetic peptide NS31406–1415 (KLVALGINAV) which elutes after
51.3 min. In all graphs, HPLC retention times are shown on the abscissa and relative signal intensity on the ordinate. Small insets in panels B and C
show mass spectra of peptides eluted at the indicated time points. (D) MSMS spectrum of the synthetic peptide NS31406–1415 (KLVALGINAV). (E) MSMS
spectrum of the natural peptide isolated from UNS3-4A/A2-27.35 cells, revealing amino acid sequence KLVALGINAV identical to the synthetic peptide
shown in panel A. Identified amino acid sequences of peptide fragments are indicated on the top of the peaks. Due to the protonated N-terminal
lysine residue, the b series of peptide fragments is dominating the MSMS spectra.
doi:10.1371/journal.pone.0029286.g004
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tion as well as recognition, thereby contributing to the under-
standing of HCV pathogenesis.
Materials and Methods
Establishment and characterization of inducible cell lines
U-2 OS human osteosarcoma-derived cell lines inducibly
expressing the HCV NS3-4A complex (UNS3-4A-24) or the
entire HCV polyprotein (UHCVcon-57.3) derived from the HCV
H77 isolate (genotype 1a) have been described previously [8,9].
These cells were stably transfected with a cytomegalovirus (CMV)
promoter-driven genomic HLA-A2 construct to augment MHC
class I expression, as described previously [10]. In brief, cells were
cotransfected with pCMV/HLA-A2 and pTK-Hyg (Clontech,
Palo Alto, CA) followed by selection with 500 mg/ml G418 (for the
selection of the tetracycline-regulated transactivator, tTA), 1 mg/
ml puromycin (for the selection of the HCV expression construct
driven by a tTA-dependent promoter), and 100 mg/ml hygro-
mycin (for the selection of the HLA-A2 expression construct).
Stable transfectants were cloned and screened for high-level HLA-
A2 expression by flow cytometry, as specified below. Tightly
regulated expression of HCV proteins was confirmed by
immunoblot analyses which were performed as described
previously [17]. Clones UNS3-4A/A2-27.35 and UHCV/A2-27
were selected for further experiments.
Immunofluorescence microscopy
Indirect Immunofluorescence was performed as described
previously [17]. The specific antibodies against NS3 (1B6) and
NS5A (11H) have been described elsewhere [8,18].
Peptides and antibodies for flow cytometry
Peptides with the amino acid sequence CINGVCWTV and
ALYDVVTKL were synthesized with free amino and carboxyl
termini by standard Fmoc chemistry (Genaxxon BioScience, Ulm,
Germany). The peptides were dissolved and diluted as described
previously [19]. Fluorescein isothiocyanate- or phycoerythrin-
labeled anti-HLA-A2, anti-CD8 and anti-IFN-c antibodies as well
as isotype-matched control antibodies were from Becton Dick-
inson (Heidelberg, Germany) and were used following the
manufacturer’s recommendations.
CD8+ T cell lines
Blood samples were obtained from two HLA-A2-positive
patients with chronic HCV infection after written informed
consent and in accordance with the 1975 Declaration of Helsinki,
federal guidelines as well as the local ethics committee as described
previously [20]. T cell lines raised against the epitopes
CINGVCWTV and ALYDVVTKL, localized within NS3 and
NS5B, respectively, were referred to as B7 and B22.
Intracellular IFN-c staining
Intracellular IFN-c staining was performed essentially as
described [19]. In brief, T cells (26105 per 96-well) were
stimulated either directly with peptides (10 mg/ml) or by UNS3-
4A/A2-27.35 and UHCV/A2-27 cell lines in the presence of
50 U/ml human recombinant interleukin 2 (Hoffmann La Roche,
Basel, Switzerland) and 1 ml/ml brefeldin A (Becton Dickinson,
Heidelberg, Germany). As a positive control, UNS3-4A/A2-27.35
and UHCV/A2-27 were externally loaded with the corresponding
synthetic peptide before the coculture. Cocultivation experiments
of T cell lines with UNS3-4A/A2-27.35 and UHCV/A2-27 cells
were performed at an effector-to-target ratio of 1:1. After 5 h of
incubation (37uC, 5% CO2), cells from each well were blocked
with IgG1 antibodies and stained with antibodies against CD8.
After permeabilization with Cytofix/Cytoperm (Becton Dickinson,
Heidelberg, Germany), cells were stained with antibodies against
IFN-c and fixed in 2% paraformaldehyde. Samples were acquired
on a FACS Canto II flow cytometer (Becton Dickinson,
Heidelberg, Germany) and analyzed with FlowJo v8.8.6 software
(TreeStar, Ashland, OR).
Cell culture and large-scale expansion
UNS3-4A/A2-27.35 and UHCV/A2-27 cells were grown in
Dulbecco’s modified Eagle medium (DMEM), 10% fetal bovine
serum, 500 mg/ml G418, 1 mg/ml puromycin, 100 mg/ml hygro-
mycin and 1 mg/ml tetracycline. For large-scale expansion, cells
were initially expanded in 15-cm culture dishes and then seeded
into a forty-tray array (Nunc Cell Factories, Nalge Nunc
International, Naperville, IL). Tetracycline was withdrawn to
induce expression of the HCV proteins, followed one week later by
detachment with Accutase (PAA, Pasching, Austria), harvesting
and washing of the cell pellets.
Isolation of MHC class I molecules, peptide elution and
sequencing
HLA-presented peptides were obtained by immunoprecipita-
tion of HLA molecules from cell lines UNS3-4A/A2-27.35 and
UHCV/A2-27. One volume of 26 lysis buffer containing PBS,
0.6% CHAPS, and complete protease inhibitor (Roche Diagnos-
tics, Basel, Switzerland) was added to shock-frozen cell pellets.
Subsequently, cells were homogenized by stirring for 1 h at 4uC.
After four times 30 s sonication, the sample was stirred again for
1 h and subsequently centrifuged at 3,0006 g, 4uC for 20 min,
and afterwards at 150,0006 g, 4uC for 1 h, to remove cell debris.
Finally, the supernatant was passed through a 0.2-mm filter
(Sartorius, Go¨ttingen, Germany).
For immunoprecipitation, lysates were applied for at least 12 h
to a CNBr-activated Sepharose 4B column (40 mg Sepharose per
mg tissue; GE Healthcare, Mu¨nchen, Germany) to which the
HLA-A-, HLA-B-, and HLA-C-specific antibody W6/32 had been
coupled (1 mg antibody per mg tissue), as described by the
manufacturer. After binding, the column was rinsed with 250 ml
PBS and subsequently with 500 ml double-distilled water. For
elution and dissociation of bound HLA-peptide complexes, the
column was shaken at least four times in one bed volume of 0.1%
trifluoroacetic acid (TFA) for 20 min at room temperature. The
four TFA eluates were subsequently collected and combined.
Finally, the HLA-presented peptides were isolated by ultrafiltra-
tion through a Centricon 10-kDa cutoff membrane (Millipore,
Billerica, MA). For LC-MS, samples were freeze-dried and
resuspended in 0.1% formic acid.
HLA-extracted peptide pools were separated by reverse-phase
HPLC (Ultimate Dionex, Amsterdam, Netherlands) and analyzed by
nano-ESI MS on a Q-TOF MS/tandem MS (Micromass,
Manchester, UK), as described [21]. Fragment spectra were analyzed
manually and database searches (National Center for Biotechnology
Information) were carried out using Multiple Alignment System for
Protein Sequences Based on Three-way Dynamic Programming
(MASCOT, http://www.matrixscience.com). Mass chromatograms
of ionized synthetic peptides NS31406–1415 (KLVALGINAV) and
NS5B2594–2602 (ALYDVVSKL) were used as references to identify
peaks of interest.
Supporting Information
Figure S1 Detection of peptide NS5B2594–2602 in MHC
class I ligands isolated from UHCV/A2-27 cells. Naturally
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processed MHC class I ligands of UHCV/A2-27 cells were
separated by high performance liquid chromatography (HPLC)
and analyzed by mass spectrometry. (A) Mass chromatogram of
the total ion current (TIC). (B) In the mass chromatogram for m/
z= 504.3 a signal peak is detected at retention time t = 63.5 min
which was further analyzed by tandem mass spectrometry (MS/
MS) (cf. Fig. S2).
(TIF)
Figure S2 Identification of the NS5B2594–2602 epitope in
UHCV/A2-27 cell-derived MHC class I ligands. (A)
UHCV/A2-27 cell-derived peptide (cf. Fig. S1) and (B) the synthetic
peptide NS5B2594–2602 (ALYDVVSKL) were both detected with
m/z=504.3 at a retention time of t = 63.2 min and subsequently
analyzed by tandem mass spectrometry (MS/MS). Fragmentation
spectra of the synthetic peptide and the natural peptide are shown in
panels A and B, respectively. Analysis of the natural peptide reveals
amino acid sequence ALYDVVSKL and is identical to that of the
synthetic peptide. Identified amino acid sequences of peptide
fragments are indicated on top of the peaks. Due to the protonated
lysine residue close to the C-terminal residue, the y series of peptide
fragments is dominating the MSMS spectra.
(TIF)
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